Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 8, 2022
Definitive chemoradiation or radiation therapy alone for the management of vulvar cancerParul Nafees Barry, Diane C Ling, Sushil Beriwal
Cancer Journal (Sudbury, Mass.)|July 22, 2016
Stereotactic Body Radiation Therapy for Recurrent Head and Neck CancerDiane C Ling, John A Vargo, Dwight E Heron
Practical Radiation Oncology|February 8, 2016
Underutilization of radiation therapy in early-stage marginal zone lymphoma negatively impacts overall survivalDiane C Ling, John A Vargo, Goundappa K Balasubramani, et al.
Clinical Lung Cancer|August 26, 2015
Comparison of Toxicity Between Intensity-Modulated Radiotherapy and 3-Dimensional Conformal Radiotherapy for Locally Advanced Non-small-cell Lung CancerDiane C Ling, Clayton B Hess, Allen M Chen, et al.
Journal of Oncology Practice|December 12, 2018
Lag Time Between Evidence and Guidelines: Can Clinical Pathways Bridge the Gap?Joshua L Rodríguez-Lopéz, Diane C Ling, Dwight E Heron, et al.
Seminars in Radiation Oncology|November 28, 2017
Role of Immunotherapy in Head and Neck CancerDiane C Ling, Chris J Bakkenist, Robert L Ferris, et al.
Advances in Radiation Oncology|April 14, 2020
Regional Recurrence Rates With or Without Complete Axillary Dissection for Breast Cancer Patients with Node-Positive Disease on Sentinel Lymph Node Biopsy after Neoadjuvant ChemotherapyDiane C Ling, Nick A Iarrobino, Colin E Champ, et al.
Brachytherapy|September 16, 2018
Declining brachytherapy utilization for high-risk prostate cancer-Can clinical pathways reverse the trend?Diane C Ling, Pooja Karukonda, Ryan P Smith, et al.
Gynecologic Oncology|January 3, 2019
Outcomes after definitive re-irradiation with 3D brachytherapy with or without external beam radiation therapy for vaginal recurrence of endometrial cancerDiane C Ling, John A Vargo, Scott M Glaser, et al.
American Journal of Clinical Oncology|October 24, 2019
Cost-Effectiveness Analysis of Upfront SBRT for Oligometastatic Stage IV Non-Small Cell Lung Cancer Based on Mutational StatusHayeon Kim, John A Vargo, Diane C Ling, et al.
Pageof 4